Cite
HARVARD Citation
Chacra, A. et al. (2017). A randomised, double‐blind, trial of the safety and efficacy of omarigliptin (a once‐weekly DPP‐4 inhibitor) in subjects with type 2 diabetes and renal impairment. International journal of clinical practice. 71 (6), p. n/a. [Online].